BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality.
According to the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares (ADS). This gives an aggregate equity value of around $1.25bn for CureVac.
The transaction will see BioNTech assimilate its former rival in the Covid-19 vaccine arena. The pharma companies said the deal will 鈥渂ring together two highly complementary companies based in Germany鈥� that can 鈥渇ully realise the transformative potential of mRNA medicine鈥�.
Shares in BioNTech rose 0.17% at market open on 12 July, reaching a price of $105.64, following the announcement. The pharma company has a market cap of $25.3bn.
The agreement underscores BioNTech鈥檚 strategy to become a dominant player in mRNA-based cancer immunotherapies. The company has struggled with revenue in recent years as demand waned for Covid-19-related products. However, it could be well positioned to harness the oncology market given its strong expertise in mRNA technology 鈥� a modality that has already showed promise in clinical trials.聽
鈥淏ioNTech aims to strengthen the research, development, manufacturing, and commercialisation of investigational mRNA-based cancer immunotherapy,鈥� BioNTech said in a statement accompanying the acquisition.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn July 2024, CureVac streamlined its focus towards oncology after selling influenza and Covid-19 vaccine development to GSK in a deal worth nearly 鈧�1.5bn.
This is the second big oncology deal for BioNTech this month, after MSD licensed a bispecific cancer drug from the company in a deal rising to a potential $11bn.
BioNTech鈥檚 CEO Ugur Sahin said: 鈥淭his transaction is another building block in BioNTech鈥檚 oncology strategy and an investment in the future of cancer medicine.
鈥淲e intend to bring together complementary capabilities and leverage technologies with the goal of advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years.鈥�
BioNTech also bolstered its cancer platform in November 2024 when it acquired oncology biotech Biotheus for an upfront payment of $800m.
